English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Rev Bras Psiquiatr. 2006;28(4):339-42 effects of milnacipran on anxiety, it has been reported to be efficacious in the treatment of depression in patients with schizophrenia spectrum disorders. Six outpatients (4 males, 2 females) diagnosed with schizophrenia according to the DSM-IV and intense anxiety symptoms, although not meeting the criteria for any DSM-IV anxiety disorder, were studied in order to determine the efficacy of milnacipran in reducing anxiety symptoms in this population. All patients were under treatment with clozapine for refractory schizophrenia. The mean age of the subjects was 35 ± 5 years. The mean daily doses of clozapine and milnacipran were 700 mg and 100 mg, respectively. All subjects were submitted to blood workups as recommended for clozapine-treated patients. No hematologic abnormalities were found in this group. The efficacy of milnacipran in reducing anxiety symptoms, as characterized according to the Hamilton Anxiety Scale (HAMA), which was applied before treatment (T0), after 4 weeks of treatment (T4) and after 8 weeks of treatment (T8). The Brief Psychiatric Rating Scale (BPRS) was also applied at T0, T4 and T8 in order to evaluate possible worsening of schizophrenia symptoms due to treatment with the antidepressant. Comparisons between groups were made using paired Student’s t-tests. Table 1 shows the demographic data for the patients treated with milnacipran, as well as variations between T0 HAM-A and BPRS scores and those obtained at T4 and T8. The mean HAMA scores decreased significantly (p = 0.014) from T0 (32 ± 7) to T4 (27 ± 9), remaining stable between T4 and T8 (28 ± 10; p = 0.523). From T0 to T8, a trend toward decreasing HAM-A was found (p = 0.069). The mean BPRS score remained virtually unchanged (p = 0.087) from T0 (71 ± 18) to T4 (67 ± 21), from T4 to T8 (66 ± 24) (p = 0.884) and from T0 to T8 (p = 0.326). No patient reported adverse effects related to the treatment. Clearly, the small size of our sample precludes generalization, and studies involving larger samples are needed to confirm these findings. However, our results suggest that milnacipran might be effective in reducing anxiety symptoms in the fourth week of use, and this effect might be maintained until the eighth week of use. In addition, the tolerability profile and the low potential for drug interactions presented by milnacipran could make it a very useful alternative for treating anxiety in patients using clozapine, without the risk of drug interactions and worsening psychotic symptoms.

Autopercepção da comunicação oral no tratamento de adolescentes usuários de drogas